Skip to content

Lunai Bioworks Inc.: 10-Q/A filed 2025-02-19

What Lunai Bioworks Inc. reported in its quarterly report amendment filed 2025-02-19 (fiscal Q3 2024): 43 published measures, 134 facts as tagged in accession 0001731122-25-000250.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2025-02-19
Fiscal period
fiscal Q3 2024
Accession
0001731122-25-000250 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lunai Bioworks Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-03-31178,089,340USD
At 2023-06-3058,300,796USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-03-3143,683,784USD
At 2023-06-3011,798,685USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-03-31134,405,556USD
At 2023-12-3143,595,536USD
At 2023-09-3046,746,312USD
At 2023-06-3046,502,111USD
At 2023-03-3166,128,153USD
At 2022-12-3166,899,356USD
At 2022-09-3070,324,842USD
At 2022-06-3072,618,848USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-03-31312,697USD
At 2023-06-301,874,480USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-58,990,070USD91
2023-07-01 to 2024-03-31-72,694,219USD275
2023-10-01 to 2023-12-31-4,529,121USD92
2023-07-01 to 2023-09-30-9,175,028USD92
2023-01-01 to 2023-03-31-4,328,296USD90
2022-07-01 to 2023-03-31-16,485,804USD274
2022-10-01 to 2022-12-31-4,457,748USD92
2022-07-01 to 2022-09-30-7,699,760USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-07-01 to 2024-03-31-8,557,649USD275
2022-07-01 to 2023-03-31-9,512,937USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-07-01 to 2024-03-3146,878USD275
2022-07-01 to 2023-03-3123,633USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-07-01 to 2024-03-318,050,737USD275
2022-07-01 to 2023-03-313,267,008USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-07-01 to 2024-03-31-1,206,806USD275
2022-07-01 to 2023-03-31-23,633USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-03-31-316,723,472USD
At 2023-06-30-244,029,253USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-03-31109,249,637shares91
2023-07-01 to 2024-03-3179,754,095shares275
2023-01-01 to 2023-03-3155,974,605shares90
2022-07-01 to 2023-03-3155,524,511shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-03-31109,249,637shares91
2023-07-01 to 2024-03-3179,754,095shares275
2023-01-01 to 2023-03-3155,974,605shares90
2022-07-01 to 2023-03-3155,524,511shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-0.54USD/shares91
2023-07-01 to 2024-03-31-0.91USD/shares275
2023-01-01 to 2023-03-31-0.08USD/shares90
2022-07-01 to 2023-03-31-0.3USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-0.54USD/shares91
2023-07-01 to 2024-03-31-0.91USD/shares275
2023-01-01 to 2023-03-31-0.08USD/shares90
2022-07-01 to 2023-03-31-0.3USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-03-31488,915USD
At 2023-06-30508,989USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-03-311,861,601USD91
2023-10-01 to 2023-12-31999,228USD92
2023-07-01 to 2023-09-30983,829USD92
2023-01-01 to 2023-03-31968,203USD90
2022-10-01 to 2022-12-31819,955USD92
2022-07-01 to 2022-09-301,026,008USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-51,380,840USD91
2023-07-01 to 2024-03-31-64,535,029USD275
2023-01-01 to 2023-03-31-4,063,436USD90
2022-07-01 to 2023-03-31-15,621,918USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-03-311,219,915USD
At 2023-06-302,565,405USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-03-3120,874,013USD
At 2023-06-3011,023,098USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2024-03-31164,186,852USD
At 2023-06-3011,640,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-03-3131,042USD
At 2023-06-3039,676USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-01-01 to 2024-03-3151,380,840USD91
2023-07-01 to 2024-03-3164,535,029USD275
2023-01-01 to 2023-03-314,063,436USD90
2022-07-01 to 2023-03-3115,621,918USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-03-311,087,156USD91
2023-07-01 to 2024-03-312,274,321USD275
2023-01-01 to 2023-03-31239,137USD90
2022-07-01 to 2023-03-313,170,471USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-03-31150,913,997shares
At 2023-06-3063,698,144shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-03-31312,697USD
At 2023-06-301,874,480USD
At 2023-03-312,948,042USD
At 2022-06-309,172,142USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-03-31450,079,965USD
At 2023-06-30290,554,875USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2024-03-311,033,970USD
At 2023-06-30-29,882USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-03-311,385,619USD
At 2023-06-30913,985USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-03-311,036,909USD
At 2023-06-30973,788USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-03-31547,994USD
At 2023-06-30464,799USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-03-31176,380,510USD
At 2023-06-3055,226,402USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-03-313,754,976USD
At 2023-06-30723,173USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-57,928,869USD91
2023-07-01 to 2024-03-31-71,630,367USD275
2023-01-01 to 2023-03-31-4,330,406USD90
2022-07-01 to 2023-03-31-16,487,753USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-317,652,379USD91
2023-07-01 to 2024-03-3119,558,981USD275
2023-01-01 to 2023-03-313,796,057USD90
2022-07-01 to 2023-03-3112,365,960USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-01-01 to 2024-03-3129,526USD91
2023-07-01 to 2024-03-3183,203USD275
2023-01-01 to 2023-03-3126,662USD90
2022-07-01 to 2023-03-3180,915USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-01-01 to 2024-03-3130,305USD91
2023-07-01 to 2024-03-3190,727USD275
2023-01-01 to 2023-03-3128,242USD90
2022-07-01 to 2023-03-3185,487USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-01-01 to 2024-03-31779USD91
2023-07-01 to 2024-03-317,524USD275
2023-01-01 to 2023-03-311,580USD90
2022-07-01 to 2023-03-314,572USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-01-01 to 2024-03-31303,802USD91
2023-07-01 to 2024-03-31758,057USD275
2023-01-01 to 2023-03-31122,289USD90
2022-07-01 to 2023-03-31310,766USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-7,609,230USD91
2023-07-01 to 2024-03-31-8,159,190USD275
2023-01-01 to 2023-03-31-264,860USD90
2022-07-01 to 2023-03-31-863,886USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-07-01 to 2024-03-3112,692USD275
2022-07-01 to 2023-03-3143,627USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2023-07-01 to 2024-03-310USD275
2022-07-01 to 2023-03-310USD274

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2024-01-01 to 2024-03-31108,441USD91
2023-07-01 to 2024-03-31232,237USD275
2023-01-01 to 2023-03-3198,950USD90
2022-07-01 to 2023-03-31339,993USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-07-01 to 2024-03-312,110,232USD275
2022-07-01 to 2023-03-313,069,487USD274

Inspect the source

Entity
Lunai Bioworks Inc. / CIK 0001527728
Captured
2026-09-19T11:18:43.497Z
SEC response SHA-256
ac98dc0ce9d3f6a81ccca9ca1f946e5772f94eabe3529dac2d726fef17abed57

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001527728.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))